332 related articles for article (PubMed ID: 32321898)
1. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
Sakamaki A; Yokoyama K; Yamazaki F; Kamimura H; Kamimura K; Takamura M; Yokoyama J; Terai S
Intern Med; 2020 Aug; 59(15):1849-1853. PubMed ID: 32321898
[TBL] [Abstract][Full Text] [Related]
2. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
4. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.
Fujiwara Y; Suzuki K; Yusa K; Eizuka M; Miura M; Watanabe Y; Takahashi H; Takikawa Y
Intern Med; 2021; 60(7):1027-1033. PubMed ID: 33790139
[TBL] [Abstract][Full Text] [Related]
6. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
7. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
8. Update on the Therapeutic Management of Hepatic Encephalopathy.
Kornerup LS; Gluud LL; Vilstrup H; Dam G
Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
[TBL] [Abstract][Full Text] [Related]
9. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
11. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.
Furnari M; De Alessandri A; Cresta F; Haupt M; Bassi M; Calvi A; Haupt R; Bodini G; Ahmed I; Bagnasco F; Giannini EG; Casciaro R
J Gastroenterol; 2019 Mar; 54(3):261-270. PubMed ID: 30232597
[TBL] [Abstract][Full Text] [Related]
12. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
13. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.
Yokoyama K; Sakamaki A; Takahashi K; Naruse T; Sato C; Kawata Y; Tominaga K; Abe H; Sato H; Tsuchiya A; Kamimura K; Takamura M; Yokoyama J; Terai S
PLoS One; 2022; 17(2):e0264459. PubMed ID: 35213654
[TBL] [Abstract][Full Text] [Related]
14. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
Hudson M; Schuchmann M
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
[TBL] [Abstract][Full Text] [Related]
15. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
[TBL] [Abstract][Full Text] [Related]
16. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
[TBL] [Abstract][Full Text] [Related]
17. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
Wang Z; Chu P; Wang W
Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
19. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]